RS BioTherapeutics – The Pulmonary Inflammation Company

RS BioTherapeutics' first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the ...

Press – RS BioTherapeutics

... lung diseases characterized by pulmonary inflammation. RS BioTherapeutics is ... Corporate Secretary with Vaxcyte, Inc., a vaccine development company.

RS BioTherapeutics, Inc. - LinkedIn

RS BioTherapeutics, Inc. | 792 followers on LinkedIn. The Pulmonary Inflammation Company | The mission of RS BioTherapeutics is to develop ...

Press Archives - RS BioTherapeutics

... therapeutics for pulmonary and systemic diseases. We are excited to ... Inc., and Marshall University using a mouse model of pulmonary inflammation.

RS BioTherapeutics Creates Therapeutic Expert Council to

... pulmonary inflammation. RS BioTherapeutics is developing a first-in-class, steroid-free, multi-targeted immune modulator (RSBT-001) for the ...

RS BioTherapeutics - P2PMarketData Company Profile

... pulmonary inflammation. RS BioTherapeutics' first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to ...

RS BioTherapeutics - StartEngine

... company with a mission of pioneering innovation in respiratory ... RS BioTherapeutics tackles a market ripe with opportunity, targeting lung inflammation ...

RS BioTherapeutics - Crunchbase Company Profile & Funding

... lung diseases characterized by pulmonary inflammation. RS BioTherapeutics is developing a first-in-class, steroid-free, multi-targeted immune modulator ...

RS BioTherapeutics Selected for Presentation at American Thoracic ...

... pulmonary inflammation. RS BioTherapeutics is developing a first-in-class, steroid-free, multi-targeted immune modulator (RSBT-001) for the treatment of ...

RS BioTherapeutics, University of Colorado School of Medicine ...

... lung diseases characterized by pulmonary inflammation. The company's Chief Medical Officer, Dr. Michelle L. Shuffett, expressed enthusiasm ...

RS BioTherapeutics Company Profile 2024 - PitchBook

... inflammatory and therapeutic power of specific cannabinoids in the treatment of chronic and acute pulmonary inflammation-based diseases. The company uses a ...

RS BioTherapeutics Announces Research Collaboration with

... lung diseases characterized by pulmonary inflammation. RS ... Company ProfileRS BioTherapeutics Industry: PharmaceuticalsWebsite: https ...

RS BioTherapeutics Launches Crowdfunding Campaign Through ...

... respiratory diseases characterized by pulmonary inflammation,” says RS BioTherapeutics' Chief Executive Officer, Dean Hart. “Our first ...

RS BioTherapeutics Secures $3 Million Seed II Round of Funding

In August, the company announced that it is planning a biotherapeutics ... pulmonary inflammation-based diseases. More information on RS ...

RS BioTherapeutics - Company Profile - Tracxn

... inflammation and alveolar macrophages to prevent the progression of both acute and chronic pulmonary inflammation related to respiratory diseases. Key ...

RS BioTherapeutics | VentureRadar

Develops RSBT-001, a nebulized cannabidiolic acid complex targeting acute and chronic pulmonary inflammation in respiratory diseases, with enhanced ...

RS Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

... respiratory diseases characterized by pulmonary inflammation,” says RS BioTherapeutics' Chief Executive Officer, Dean Hart. “Our first investigational ...

RS BioTherapeutics Selects Recipharm as Product Characterization ...

... therapeutics for pulmonary and systemic diseases. We are excited to ... pulmonary inflammation-based diseases. More information on RS ...

The Big Idea CONNECTpreneur Networking and Pitch Extravaganza

RS BioTherapeutics is developing a first-in-class agent for deadly respiratory illnesses with no cure. https://rsbiotherapeutics.com/ ...

RS BioTherapeutics Careers, Perks + Culture - Built In

Companies RS BioTherapeutics Overview. RS ... inflammation and modulation of alveolar macrophages responsible for fibrotic changes within the lungs.

RS BioTherapeutics, Inc.

Biotechnology company